Sorin SpA Receives SFDA Approval and Launches REPLY and ESPRIT Families of Pacemakers in China

Sorin SpA announced that it has received the marketing approval from China’s State Food and Drug Administration (SFDA) and announced the full commercial launch in China of the REPLY and ESPRIT families of pacemakers. Both families include easy-to-use functions and patient safety features. The REPLY and ESPRIT families have several common attributes such as some of the industry’s smallest devices, longevity, and SMARTCHECK, a tool designed to simplify device checks by automating follow up tests at the click of a button.